Phase II study of sunitinib in patients with metastatic urothelial cancer

Journal of Clinical Oncology

Volumn 28, Issue 8, 2010, Pages 1373-1379

  Gallagher, David J ^a   Milowsky, Matthew I ^a   Gerst, Scott R ^a   Ishill, Nicole ^a   Riches, Jamie ^a   Regazzi, Ashley ^a   Boyle, Mary G ^a   Trout, Alisa ^a   Flaherty, Anne Marie ^a   Bajorin, Dean F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER; BLADDER CANCER; BLADDER UROTHELIAL CANCER; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMATURIA; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY PELVIS; LEUKOPENIA; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTHROMBIN TIME; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; ULCER; URETER; URETHRA; URINARY CLOT RETENTION; URINARY DYSFUNCTION; UROTHELIAL CANCER; VISCERAL METASTASIS; VOMITING; WEIGHT REDUCTION; BLADDER TUMOR; CLINICAL TRIAL; DOSE RESPONSE; METASTASIS; MIDDLE AGED; NEOPLASM; PATHOLOGY; SURVIVAL; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; PYRROLES; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 77950474660     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.3922     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Cookson MS, Herr HW, Zhang ZF, et al: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158:62-67, 1997 (Pubitemid 27251595)
3. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19:666-675, 2001 (Pubitemid 32120143)
4. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006 (Pubitemid 46630489)
5. Saltz LB, Rosen LS, Marshall JL, et al: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799, 2007 (Pubitemid 350086483)
6. Socinski MA, Novello S, Brahmer JR, et al: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656, 2008 (Pubitemid 351264362)
7. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006 (Pubitemid 44528723)
8. Burstein HJ, Elias AD, Rugo HS, et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816, 2008
9. Patel AR LW, Smith AK, et al: Quantification of sunitinib's antitumor effects in a localized orthotopic bladder cancer model. Proceeding of The American Urologic Association's Annual Meeting, April 25-29, 2009, Chicago, IL
10. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
11. Srinivas S, Roigas J, Gillessen S, et al: Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results. J Clin Oncol 25:244s. 2007 (abstr 5040)
12. George S, Blay JY, Casali PG, et al: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959-1968, 2009
13. Theodoropoulos VE, Lazaris AC, Kastriotis I, et al: Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 95:425-431, 2005 (Pubitemid 40283138)
14. Wu W, Shu X, Hovsepyan H, et al: VEGF receptor expression and signaling in human bladder tumors. Oncogene 22:3361-3370, 2003 (Pubitemid 36713733)
15. Houk BE, Bello CL, Michaelson MD, et al: Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/ pharmacodynamic (PKPD) approach. J Clin Oncol 25:241s, 2007 (abstr 5027)
16. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
17. Chodak GW, Scheiner CJ, Zetter BR: Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells. N Engl J Med 305:869-874, 1981 (Pubitemid 11005198)
18. Bochner BH, Cote RJ, Weidner N, et al: Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87:1603-1612, 1995
19. McCaffrey JA, Hilton S, Mazumdar M, et al: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15:1853-1857, 1997
20. Vaughn DJ, Broome CM, Hussain M, et al: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20:937-940, 2002 (Pubitemid 34141835)
21. Witte RS, Elson P, Bono B, et al: Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15:589-593, 1997 (Pubitemid 27074226)
22. Witte RS, Manola J, Burch PA, et al: Topotecan in previously treated advanced urothelial carcinoma: An ECOG phase II trial. Invest New Drugs 16:191-195, 1998 (Pubitemid 28495223)
23. Milowsky MI, Tickoo SK, Gallagher DJ, et al: Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). ECCO Annual Meeting Proceedings, February 12-15, 2007, San Francisco, CA
24. Lorusso V, Pollera CF, Antimi M, et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34:1208-1212, 1998 (Pubitemid 28342111)
25. Culine S, Theodore C, De Santis M, et al: A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94:1395-1401, 2006 (Pubitemid 43772272)
26. Winquist E, Vokes E, Moore MJ, et al: A phase II study of oxaliplatin in urothelial cancer. Urol Oncol 23:150-154, 2005 (Pubitemid 40720378)
27. Sweeney CJ, Roth BJ, Kabbinavar FF, et al: Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24:3451-3457, 2006 (Pubitemid 46638903)
28. Galsky MD, Mironov S, Iasonos A, et al: Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 25:265-270, 2006
29. Roth BJ, Manola J, Dreicer R, et al: Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): A phase II trial of the Eastern Cooperative Oncology Group. Invest New Drugs 20:425-429, 2002 (Pubitemid 35252786)
30. Wülfing C, Machiels J, Richel D, et al: A single arm, multicenter, open label, ph II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. J Clin Oncol 23:401s, 2005 (abstr 4594)
31. Fechner G, Siener R, Reimann M, et al: Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO trial AB 20/99). Int J Clin Pract 60:27-31, 2006 (Pubitemid 43732573)
32. Patel PH, Chadalavada RS, Ishill NM, et al: Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 26:252s, 2008 (abstr 5008)
33. Milowsky MI TS, Gallagher DJ, et al: HIF and mTOR pathways in invasive urothelial carcinoma: A study with potential therapeutic implications. Am Soc Clin Oncol Genitourinary Symposium, 2008
34. Casali PG, Garrett CR, Blackstein ME, et al: Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol 24:523s, 2006 (abstr 9513)
35. Choi H, Charnsangavej C, de Castro Faria S, et al: CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. Am J Roentgenol 183:1619-1628, 2004 (Pubitemid 44210530)
36. Schwartz LH, Bogaerts J, Ford R, et al: Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 45:261-267, 2009
37. Sonpavde G, Jian W, Liu H, et al: Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 27:391-399, 2009
38. Cuneo KC, Geng L, Fu A, et al: SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 71:873-879, 2008 (Pubitemid 351749533)